Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: quetiapine fumarate (Seroquel) Clear all
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

NCT00329446
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Quetiapine Fumarate, Escitalopram oxylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

NCT00156715
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Quetiapine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 9, 2026, 9:10 PM EDT
Terminated Phase 3 Interventional

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

NCT00396214
View directory record Official record
Conditions
Schizophrenia
Interventions
Bifeprunox, Quetiapine
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
69
States / cities
Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
View directory record Official record
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 3 Interventional

A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder

NCT00232414
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

NCT00208143
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
Interventions
Quetiapine, Risperidone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

NCT02901587
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
21 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 4 Interventional Results available

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

NCT00457366
View directory record Official record
Conditions
Agitation
Interventions
Quetiapine, Haloperidol, Lorazepam, Cogentin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Oct 9, 2026, 9:10 PM EDT
Not listed Not applicable Interventional

Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia

NCT00231101
View directory record Official record
Conditions
Smoking Behavior in Schizophrenia
Interventions
Quetiapine
Drug
Lead sponsor
Arthur P. Noyes Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2006 · Synced Oct 9, 2026, 9:10 PM EDT
Terminated Phase 2 Interventional

A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study

NCT00584688
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
quetiapine
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder

NCT00388973
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
66 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Oct 9, 2026, 9:10 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

NCT00771134
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lu AA39959, Placebo, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

NCT00060489
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
SEROQUEL (quetiapine fumarate) Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
27
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Not applicable Interventional

Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions

NCT01570959
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Garden Grove, California • National City, California • North Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 4 Interventional

An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence

NCT00223210
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence
Interventions
Quetiapine, PLacebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 3 Interventional

Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms

NCT00277667
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 4 Interventional

Quetiapine Compared With Placebo in the Management of Fibromyalgia

NCT01458964
View directory record Official record
Conditions
Fibromyalgia
Interventions
Quetiapine
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 9, 2026, 9:10 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans

NCT01662297
View directory record Official record
Conditions
Insomnia, Mental Health Disorder, Substance Use Disorder
Interventions
Quetiapine, Trazodone
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Phase 3 Interventional

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

NCT00654706
View directory record Official record
Conditions
Schizophrenia, Cognition
Interventions
Sertindole, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
26
States / cities
Garden Grove, California • National City, California • Pasadena, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 9, 2026, 9:10 PM EDT
Completed Not applicable Interventional Results available

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

NCT00617396
View directory record Official record
Conditions
Functional Bowel Disorders
Interventions
Quetiapine (50 mg/day-100mg/day)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 9, 2026, 9:10 PM EDT
Terminated No phase listed Observational

Trazodone vs. Quetiapine for the Treatment of ICU Delirium

NCT05307003
View directory record Official record
Conditions
Delirium, Delirium of Mixed Origin, Delirium, Sepsis Associated, Delirium in Old Age, Delirium Confusional State, Psych, Morality, Treatment Side Effects
Interventions
Trazodone, Quetiapine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 9, 2026, 9:10 PM EDT